logo
Plus   Neg
Share
Email

Genuine Parts Q1 Profit Climbs - Quick Facts

Genuine Parts Co. (GPC) reported first quarter net income of $146.26 million or $0.93 per share, up from $126.52 million or $0.80 per share a year ago. On average, six analysts polled by Thomson Reuters expected the company to report earnings of $0.87 per share. Analysts' estimates typically exclude special items.

Net sales were up to $3.18 billion from $2.97 billion in the prior-year quarter. Analysts estimated revenues of $3.16 billion.

Thomas Gallagher, Chairman and Chief Executive Officer, said,

"...In the first quarter, the Automotive Group posted a 6% sales increase. This Group has experienced steady and consistent sales growth dating back to the fourth quarter of 2009, reflecting the positive impact of our sales initiatives and the sound fundamentals in the automotive aftermarket, which continue to support a healthy marketplace. Sales for Motion Industries, our Industrial Group, remain the strongest among our four business segments, growing by 12% in the quarter. EIS, our Electrical Group, posted a 5% sales increase. Both Motion Industries and EIS have generated very strong sales growth over the last two years, driven by their internal initiatives and the recovery of the manufacturing sector of the economy..."

Gallagher concluded, "..As we turn to the second quarter, we are optimistic that our businesses will show continued progress over the balance of the year."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA. Reigniting concerns about a global trade war, President Donald Trump announced plans to impose new tariffs on billions of dollars worth of Chinese imports on Friday. Trump said in a statement the U.S. will implement a 25 percent tariff on $50 billion of goods from China that contain "industrially significant technologies."
Follow RTT